Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
- DOI
- 10.1016/j.annonc.2025.09.006
- Published
- 2026-01
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2025.09.006,
title = {Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial},
author = {R.J. Motzer and B. Escudier and M. Burotto and T. Powles and A.B. Apolo and M.T. Bourlon and A.Y. Shah and C. Porta and C. Suárez and C.H. Barrios and M. Richardet and H. Gurney and E.R. Kessler and Y. Tomita and J. Bedke and C. Scheffold and M. Askelson and J. Panzica and J. Zhang and M. van Kooten Losio and T.K. Choueiri},
year = {2026},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2025.09.006},
url = {https://doi.org/10.1016/j.annonc.2025.09.006}
}RIS
TY - JOUR TI - Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial AU - R.J. Motzer AU - B. Escudier AU - M. Burotto AU - T. Powles AU - A.B. Apolo AU - M.T. Bourlon AU - A.Y. Shah AU - C. Porta AU - C. Suárez AU - C.H. Barrios AU - M. Richardet AU - H. Gurney AU - E.R. Kessler AU - Y. Tomita AU - J. Bedke AU - C. Scheffold AU - M. Askelson AU - J. Panzica AU - J. Zhang AU - M. van Kooten Losio AU - T.K. Choueiri PY - 2026 JO - Annals of Oncology DO - 10.1016/j.annonc.2025.09.006 UR - https://doi.org/10.1016/j.annonc.2025.09.006 ER -
APA
Motzer, R., Escudier, B., Burotto, M., Powles, T., Apolo, A., Bourlon, M., Shah, A., Porta, C., Suárez, C., Barrios, C., Richardet, M., Gurney, H., Kessler, E., Tomita, Y., Bedke, J., Scheffold, C., Askelson, M., Panzica, J., Zhang, J., Losio, M. V. K., & Choueiri, T. (2026). Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Annals of Oncology. https://doi.org/10.1016/j.annonc.2025.09.006
Source records
- crossref · retrieved 2026-09-27T15:57:27.032Z